Artax Biopharma is transforming the treatment of T Cell mediated disease.
Employees: 11-50
Total raised: $44M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | Keith Vent... | keith.vc/ |
| - | Advent Lif... | adventls.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 06.08.2024 | - | $8M | - |
| 11.05.2022 | - | $26M | - |
| 22.09.2015 | Series B | $10M | - |
Mentions in press and media 13
| Date | Title | Description |
| 13.08.2024 | Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158 | AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression Psoriasis biomarker panel and PASI scores expected later this year CAMBRIDGE, Mass., Aug. 13, 2024 /PRNewswire/ -- Artax Biopharma, Inc., a clini... |
| 06.08.2024 | Artax Biopharma Raises $8 Million Ahead of Phase 2a Data Expected in Q4-2024 | Strong support from existing shareholders which includes Lilly, Advent Life Sciences, Columbus Ventures, Sound Bioventures and Belinda Termeer CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Artax Biopharma, Inc., a clinical-stage biotechnol... |
| 12.05.2022 | Columbus VP cierra la financiación de $26M en Artax Biopharma | 12/05/2022 Nota de prensa COLUMBUS CIERRA LA FINANCIACIÓN EN LA EMPRESA ARTAX BIOPHARMA. La firma de capial riesgo (venture capital) Columbus Venture Partners cierra la financiación de 26 millones de dólares en la empresa Artax Biopharma... |
| 12.05.2022 | Artax Biopharma Closes $26M Financing Round | Artax Biopharma, a Cambridge, MA-based clinical stage biotechnology company, raised $26M in funding. The round was led by Eli Lilly and Company and Sound Bioventures with participation from Advent Life Sciences, Columbus Venture Partners, a... |
| 11.05.2022 | A Y Combinator alum on how the startup hustle came at a steep cost—to her mental health | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. The following essay was contributed by Trisha Bantigue, CEO and co-founder of the San Francisco-b... |
| 11.05.2022 | Artax Biopharma Closes $26M Financing | CAMBRIDGE, MA, Artax Biopharma, a clinical stage biotechnology company, has announced the close of a $26 million financing round. >> Click here for more funding data on Artax Biopharma >> To export Artax Biopharma funding da... |
| 17.09.2020 | Artax Biopharma Announces Issuance of U.S. Composition of Matter Patent for Autoimmune Disease Program AX-158 | |
| 05.06.2020 | Artax Biopharma Raises Series B Financing Extension | Artax Biopharma, Inc., a Cambridge, Mass.-based biotechnology company focused on transforming autoimmune disease treatment, completed an extension to its Series B financing led by Columbus Venture Partners. The amount of the deal was not di... |
| 22.09.2015 | Artax raises $10M Series B for autoimmune disease small molecule drug | The underlying technology comes from Spanish National Council researcher Dr. Balbino Alarcon. He’ll continue to research the cytoplasmic adapter proteins that help activate T-cells – developing Nck inhibitors that can help shut down an auto... |
| 22.09.2015 | Artax Biopharma Raises $10M in Series B Funding | Artax Biopharma, a Cambridge, Massachusetts-based clinical stage biotechnology company developing selective oral therapies for the treatment of autoimmune diseases, raised $10M in Series B funding. The round was led by Henri Termeer, former... |
Show more